A Phase IV Randomized, Single-Blind Trial of Liposomal Bupivacaine (Exparel®) for Pain Control in Costal Cartilage Harvest

NCT05285566 Phase 4 RECRUITING

The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.

Details

Lead sponsor	Mayo Clinic
Phase	Phase 4
Status	RECRUITING
Enrolment	60
Start date	2022-05-04
Completion	2026-09

Conditions

• Nasal Surgery

Interventions

• Exparel
• Xylocaine

Primary outcomes

• Pain Scores — 7-10 days following the last administration of study treatment
  Measured using a visual analog scale 0=no pain and 10=worst possible
• Change in oral pain medication — 7-10 days following the last administration of study treatment
  Total oral pain medication usage self-reported in pain medication diary

Countries

United States